"On behalf of the Board and the team at Allogene, I would like to thank Eric for his lasting impact in establishing the Company as a leader in allogeneic CAR T. He has been an integral part of what Allogene has created and we wish only the best for Eric and his family," said David Chang, President, CEO and Co-Founder of Allogene. "While we will undoubtedly miss Eric, we are extremely excited about our next phases of growth. We've presented industry-leading data demonstrating the potential of our platform and are focused on our potentially pivotal trial and future BLA submission in lymphoma as well as making CAR T a reality in solid tumors."